You are here:Home-Inhibitors & Agonists-Cytoskeleton/Cell Adhesion Molecules-Integrin

Request The Product List ofIntegrin Integrin

Cat. No. Product Name CAS No. Information



ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis; ALG1001 inhibits an integrin-mediated pathway of the vitreoretinal interface, connecting the posterior aspect of the vitreous with the internal limiting membrane of the retina. In blocking this pathway, ALG-1001 helps to achieve vitreous breakdown and separation from the retina.

Other Indication

Phase 2 Clinical




MK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay; displays approximately 100-fold selectivity for αvβ3 over αvβ5 (IC50=10 nM), and no significant activity for the fibrinogen receptor αIIBβ3 (IC50>30 uM); shows activity in different animal models of bone turnover and has potentiation for the prevention and treatment of osteoporosis; also reduces melanoma metastasis both in vitro and in vivo.

Prostate Cancer

Phase 1 Discontinued




Cyclo(RGDyK) (Cyclic Arg-Gly-Asp-D-Tyr-Lys) is a cyclic derivative of RGD, potent, selective αVβ3 integrin inhibitor with IC50 of 20 nM; a recognition motif used by extracellular matrix proteins (vitronectin, fibrinogen, laminin, and collagen) to bind to a variety of integrins including αvβ3.


GSK-3008348 hydrochloride


GSK-3008348 hydrochloride is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).

Cystic Fibrosis

Phase 1 Clinical




GSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).

Cystic Fibrosis

Phase 1 Clinical




A novel potent, orally active ILK (integrin-linked kinase) inhibitor with IC50 of 0.6 uM; exhibits high in vitro potency against a panel of prostate and breast cancer cell lines (IC50=1-2.5 uM) with no effect on normal epithelial cells; facilitates the dephosphorylation of Akt at Ser-473 and other ILK targets, including GSK-3β and myosin light chain; suppresses the expression of the transcription/translation factor YB-1 and HER2, EGFR in PC-3 cells, induces autophagy and apoptosis; demonstrates in vivo efficacy in suppressing PC-3 xenograft tumor growth; orally active.




GLPG-0187 (GLPG0187) is a highly potent, broad spectrum integrin receptor antagonist with IC50 of 1-10 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1; significantly inhibits angiogenesis both in vivo and in vitro, osteoclastogenesis in vitro, and bone loss in vivo; inhibits de novo formation and progression of bone and visceral metastases in prostate cancer and breast cancer mice models.

Solid Tumors

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us